HCPLive

Gastric Bypass Drastically Lowers Cholesterol

TUESDAY, June 11 (HealthDay News) -- Compared to gastric banding, bariatric bypass surgery achieves greater cholesterol lowering, according to a study published in the June issue of Diabetes Care.

Alberto Benetti, MD, from Universita degli Studi di Milano, and colleagues assessed glucose metabolism (blood glucose and serum insulin levels and homeostasis model assessment of insulin resistance [HOMA-IR] index) and cholesterol metabolism (absorption: serum campesterol and sitosterol levels; synthesis: serum lathosterol levels; catabolism: rate of appearance and serum concentrations of serum 7-α- and serum 27-OH-cholesterol after infusions of deuterated 7-α- and 27-OH-cholesterol in sequence) in grade 3 obesity subjects undergoing bariatric bypass surgery and gastric banding. Measurements were taken before and six months after surgery.

The researchers found that baseline values were similar in all subjects. In both groups, weight loss and blood glucose, insulin levels, HOMA-IR, and triglycerides decreased similarly. Serum cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, serumsitosterol, and campesterol levels decreased and lathosterol levels increased only in bypass subjects. Serum 27-OH-cholesterol decreased in both groups, but only in the bypass group was there a significant increase in 7-α-OH-cholesterol.

"Malabsorptive surgery specifically affects cholesterol levels, independent of weight loss and independent of glucose metabolism and insulin resistance," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Genetic mutations may increase risk of acute and chronic pancreatitis in patients who are also heavy smokers and drinkers.
Multicenter phase II study will also evaluate pharmacokinetics of omega-3 carboxylic acids and omega-3-acid ethyl esters administered to patients with varying degrees of EPI.
$vAR$